Holly Yin

427 total citations
19 papers, 303 citations indexed

About

Holly Yin is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Holly Yin has authored 19 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Holly Yin's work include Protein Degradation and Inhibitors (4 papers), Cancer Mechanisms and Therapy (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Holly Yin is often cited by papers focused on Protein Degradation and Inhibitors (4 papers), Cancer Mechanisms and Therapy (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Holly Yin collaborates with scholars based in United States, Malaysia and United Kingdom. Holly Yin's co-authors include Jessica Schmidt, Spyro Mousses, Rodger E. Tiedemann, Hanbin Mao, Chris Sereduk, Chang-Xin Shi, Yunxi Cui, Laura A. Bruins, Aleksandar Sekulić and Vijay Gokhale and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Holly Yin

18 papers receiving 301 citations

Peers

Holly Yin

ONCOL

HEMAT

IMMUN

Hélène Lelièvre France

Valentina Agnusdei Italy

Scott E. Millman United States

Caila Ryan United States

Roel Vandepoel Belgium

Charis A. Venditti United States

Angela Rachele Soliera Italy

Rosalind Codrington United Kingdom

Les Brail United States

Zunling Li China

Hélène Lelièvre France

Holly Yin

180 ×0.8

77 ×1.1

ONCOL

38 ×0.9

HEMAT

31 ×0.7

IMMUN

57 ×1.4

Citations per year, relative to Holly Yin Holly Yin (= 1×) peers Hélène Lelièvre

Countries citing papers authored by Holly Yin

Since Specialization

Citations

This map shows the geographic impact of Holly Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly Yin more than expected).

Fields of papers citing papers by Holly Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly Yin. The network helps show where Holly Yin may publish in the future.

Co-authorship network of co-authors of Holly Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Holly Yin. A scholar is included among the top collaborators of Holly Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly Yin. Holly Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Wang, Yixing, Chen Wang, Jennifer Jossart, et al.. (2025). Discovery and Characterization of Small Molecule Inhibitors Targeting Exonuclease 1 for Homologous Recombination-Deficient Cancer Therapy. ACS Chemical Biology. 20(6). 1258–1272.

Mead, Heather, Holly Yin, George R. Thompson, et al.. (2024). In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides. Microbiology Spectrum. 12(10). e0100824–e0100824. 1 indexed citations

Gutova, Margarita, Heini M. Natri, Vikram Adhikarla, et al.. (2024). Targeting Wnt signaling for improved glioma immunotherapy. Frontiers in Immunology. 15. 1342625–1342625. 8 indexed citations

Mohanty, Atish, Michelle Afkhami, Rebecca Pharaon, et al.. (2024). Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies. Journal for ImmunoTherapy of Cancer. 12(7). e008505–e008505. 3 indexed citations

Zhang, Tiantian, et al.. (2023). Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. Journal of Clinical Medicine. 12(3). 1098–1098. 42 indexed citations

Mohanty, Atish, Rebecca Pharaon, Arin Nam, et al.. (2020). Abstract 6397: Focal adhesion kinase (FAK) inhibition overcomes cisplatin resistance in head and neck squamous cell carcinoma (HNSCC). Cancer Research. 80(16_Supplement). 6397–6397. 1 indexed citations

Pharaon, Rebecca, et al.. (2020). Differential immune pathways in classic and mixed variants of anaplastic thyroid cancer.. Journal of Clinical Oncology. 38(15_suppl). e18579–e18579. 1 indexed citations

Pharaon, Rebecca, et al.. (2020). Abstract 1525: Upregulation of genes linked to epithelial-mesenchymal transition in anaplastic thyroid cancer. Cancer Research. 80(16_Supplement). 1525–1525. 1 indexed citations

Wang, Chongkai, John Park, Ching Ouyang, et al.. (2019). Abstract 528: Radioembolization followed by durvalumab and tremelimumab does not induce immune responses against liver-metastasized MSS colorectal cancer. Cancer Research. 79(13_Supplement). 528–528. 1 indexed citations

10.

Chung, Vincent, Paul Frankel, Stephen Shibata, et al.. (2019). Abstract B13: Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer. Cancer Research. 79(24_Supplement). B13–B13. 1 indexed citations

11.

Roos, Alison, Harshil Dhruv, Ian T. Mathews, et al.. (2017). Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 8(7). 12234–12246. 36 indexed citations

12.

Karnezis, Anthony N., Yemin Wang, Pilar Ramos, et al.. (2016). Abstract A33: Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type.. Clinical Cancer Research. 22(2_Supplement). A33–A33. 2 indexed citations

13.

Kang, Hyun-Jin, Yunxi Cui, Holly Yin, et al.. (2016). A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. Journal of the American Chemical Society. 138(41). 13673–13692. 79 indexed citations

14.

Evers, Lisa, Pedro A. Pérez–Mancera, Elizabeth Lenkiewicz, et al.. (2014). STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Medicine. 6(1). 9–9. 24 indexed citations

15.

Dhruv, Harshil, Joseph C. Loftus, Pooja Narang, et al.. (2013). Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis. Journal of Biological Chemistry. 288(45). 32261–32276. 17 indexed citations

16.

Zhu, Yuan Xiao, Rodger E. Tiedemann, Chang-Xin Shi, et al.. (2011). RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 117(14). 3847–3857. 81 indexed citations

17.

Zhu, Yuan Xiao, Rodger E. Tiedemann, Jessica Schmidt, et al.. (2009). RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.. Blood. 114(22). 602–602. 1 indexed citations

18.

Yin, Holly, Jeffrey Kiefer, Donald Chow, et al.. (2009). Abstract PR-10: RNAi-directed identification of chemosensitizers of GSK923295 response. Molecular Cancer Therapeutics. 8(12_Supplement). PR–10. 1 indexed citations

19.

Tiedemann, Rodger E., et al.. (2007). Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.. Blood. 110(11). 391–391. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact